SCI Pharmtech Inc is a Taiwan-based company mainly engaged in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs), API intermediates, and specialty and precision chemicals. The Company's main product categories are APIs, API intermediates, and specialty chemicals. The Company primarily sells its products in Europe, Asia, the Americas, and other domestic and international markets.

Employees

239

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-23	NT$49.15	-1.31%	185,955
26-07-22	NT$49.80	+2.89%	331,304
26-07-21	NT$48.40	+3.64%	288,783
26-07-20	NT$46.70	+0.76%	133,577
26-07-17	NT$46.35	-1.38%	193,244

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 2026-07-23			5-day change	1st Jan Change
49.15 ^TWD	-1.31%		+4.57%	+0.92%

05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	5.87B 181M 160M 148M 136M 256M 17.57B 260M 1.77B 691M 8.57B 681M 666M 29.73B	P/E 2024	20.3x	P/E 2025	54.2x
Enterprise Value	6.79B 210M 184M 171M 158M 295M 20.3B 301M 2.05B 799M 9.9B 787M 770M 34.35B	EV / Sales 2024	7.3x	EV / Sales 2025	5.01x
Free-Float	55.34%	Yield 2024	1.66%	Yield 2025	1.54%

05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-05	SCI Pharmtech, Inc. Proposes Dividend Distribution for the Period from January 1, 2025 to December 31, 2025	CI
11-07	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-05	SCI Pharmtech, Inc. Announces Cash Dividend, Payable on August 5, 2025	CI
25-05-26	SCI Pharmtech, Inc. Announces Changes to its Board, Effective May 26, 2025	CI
25-05-08	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-10	Sci Pharmtech, Inc. Declares Dividend for Period from January 01, 2024 to December 31, 2024	CI
25-03-09	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-09	Sci Pharmtech, Inc. Announces Cash Dividend Payment	CI
24-12-20	Sci Pharmtech, Inc. Announces Appointment of Members of the Sustainable Development Committee	CI
24-11-08	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

22-06-29	SCI Pharmtech : Notice of appointment of general manager of the Board of Directors.	PU
22-06-29	SCI Pharmtech : Notice of the re-election of chairman of the Board of Directors.	PU
22-06-21	SCI Pharmtech : List of the Company's elected directors.	PU
22-06-21	SCI Pharmtech : Notice of the resolutions of 2022 general shareholders' meeting.	PU
22-06-21	SCI Pharmtech : Notice of re-election of functional committees' members	PU

SCI Pharmtech, Inc. Stock

Stocks

4119

TW0004119003

Pharmaceuticals

Valuation: SCI Pharmtech, Inc.

Chart: SCI Pharmtech, Inc.

Latest news : SCI Pharmtech, Inc.

Press Releases: SCI Pharmtech, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: SCI Pharmtech, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	-1.31%
1 week	+4.57%
Current month	+9.71%
1 month	+13.77%
3 months	+4.35%
6 months	-8.81%
Current year	+0.92%

1 week	46.1	50.2
1 month	43.5	50.2
Current year	39.6	55.5
1 year	39.6	63.2
3 years	39.6	106.5
5 years	39.6	119.56
10 years	39.6	119.56

Manager	Title	Age	Since
Wei Chun Weng CEO	Chief Executive Officer	-	-
Wen Chen Yang DFI	Director of Finance/CFO	-	2002-12-31
Wen Chih Chou PRN	Corporate Officer/Principal	-	2010-08-31

Director	Title	Age	Since
Hsiang Li Chen BRD	Director/Board Member	-	2001-12-16
Wei Chun Weng CHM	Chairman	-	2001-12-16
Wen Chih Chou BRD	Director/Board Member	-	2010-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCI PHARMTECH, INC.	-1.31%	+4.57%	-20.47%	-51.92%	181M
MERCK & CO., INC.	+2.36%	+2.23%	+55.37%	+18.20%	322B
MERCK KGAA	+0.31%	+2.13%	+22.81%	-11.65%	68.84B
HALOZYME THERAPEUTICS, INC.	+3.88%	+4.26%	+38.05%	+88.48%	9.59B
KYOWA KIRIN CO., LTD.	+0.93%	-1.38%	+1.71%	-4.10%	8.29B
SK BIOPHARMACEUTICALS CO., LTD.	+3.78%	+0.38%	-21.63%	-6.67%	4.23B
BETTA PHARMACEUTICALS CO., LTD.	+0.07%	-6.67%	-3.14%	+22.21%	3.77B
YUHAN CORPORATION	+1.71%	+0.85%	-42.97%	+11.90%	3.61B
SUPERNUS PHARMACEUTICALS, INC.	+0.53%	-2.12%	+43.13%	+54.17%	2.74B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.30%	-5.84%	+3.61%	-10.21%	2.13B
Average	+0.84%	+1.65%	+7.65%	+11.04%	42.56B
Weighted average by Cap.	-0.74%	+2.59%	+46.18%	+14.32%

	2024	2025
Net sales	1.52B 47.06M 41.39M 38.45M 35.36M 66.32M 4.56B 67.51M 460M 179M 2.22B 177M 173M 7.71B	1.34B 41.5M 36.5M 33.91M 31.19M 58.48M 4.02B 59.53M 405M 158M 1.96B 156M 152M 6.8B
Net income	535M 16.51M 14.52M 13.49M 12.41M 23.27M 1.6B 23.69M 161M 62.93M 780M 62M 60.65M 2.71B	107M 3.32M 2.92M 2.71M 2.49M 4.67M 321M 4.76M 32.4M 12.64M 157M 12.45M 12.18M 543M
Net Debt	298M 9.19M 8.08M 7.51M 6.91M 12.95M 890M 13.19M 89.81M 35.03M 434M 34.51M 33.76M 1.51B	912M 28.18M 24.78M 23.02M 21.18M 39.71M 2.73B 40.42M 275M 107M 1.33B 106M 104M 4.62B